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Following the coordinated efforts of five established scientific organizations, this report describes the ‘‘novel
cellular therapy’’ activity (i.e., cellular treatments excluding hematopoietic stem cells [HSC] for the reconstitution
of hematopoiesis) in Europe for the year 2011. Two hundred forty-six teams from 35 countries responded to the
cellular therapy survey, 126 teams from 24 countries provided data on 1759 patients using a dedicated survey
and 120 teams reported no activity. Indications were musculoskeletal/rheumatological disorders (46%; 99%
autologous), cardiovascular disorders (22%; 100% autologous), hematology/oncology, predominantly including
the prevention or treatment of graft-versus-host disease (18%; 2% autologous), neurological disorders (2%; 83%
autologous), gastrointestinal (1%; 68% autologous), and other indications (12%; 77% autologous). Autologous
cells were used predominantly for musculoskeletal/rheumatological (58%) and cardiovascular (27%) disorders,
whereas allogeneic cells were used mainly for hematology/oncology (84%). The reported cell types were
mesenchymal stem/stromal cells (56%), HSC (23%), chondrocytes (12%), dermal fibroblasts (3%), keratinocytes
(2%), and others (4%). In 40% of the grafts, cells were delivered following ex vivo expansion, whereas cells were
transduced or sorted, respectively, in 3% and 10% of the reported cases. Cells were delivered intraorgan (42%),
intravenously (26%), on a membrane or gel (16%), or using 3D scaffolds (16%). Compared to last year, the
number of teams participating in the dedicated survey doubled and, for the first time, all European Group for
Blood and Marrow Transplantation teams reporting information on cellular therapies completed the extended
questionnaire. The data are compared with those collected since 2008 to identify trends in the field. This year’s
edition specifically focuses on cardiac cell therapy.
Introduction
The clinical use of the so-called ‘‘novel cellular thera-pies,’’ namely those not aimed at the reconstitution of the
hematopoietic system, is not only a challenging target for the
scientific community, but also the subject of intense public de-
bate.1,2 The landscape includes not only the scientific and clin-
ical community together with the patients, their families, and
the lay public, but also health regulators, national health ser-
vices/health insurance companies, and service providers.
Despite the direct interest by a broad set of involved parties,
transparent access to accurate data on clinical use of cell thera-
pies is extremely limited and confined within specific sectors.
In 2008, the European sections of the Tissue Engineering
and Regenerative Medicine International Society-Europe
(TERMIS-EU), of the International Society of Cellular Therapy
(ISCT), and of the International Cartilage Repair Society
(ICRS), in a joint initiative with the European group for Blood
and Marrow Transplantation (EBMT) and the European Lea-
gue Against Rheumatism (EULAR), established a survey on
novel cellular therapies. This has allowed the number of pa-
tients treated in Europe with cells or engineered tissues to be
collected and to be sorted by specific therapeutic indications,
cell types used, and cell processing/delivery modes.3–5 The
survey aims to offer a transparent and unbiased update on the
constructive work carried out, thanks to the coordinated efforts
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of the different stakeholders, including scientists, clinicians, and
their patients, in compliance with the required authorizations.
Here, we report the results of the fourth survey for the
activity in 2011, with a comparison to the previously iden-
tified trends and a specific discussion on cell-based treat-
ments in the field of cardiovascular therapy. The information
presented is complementary to that available in published
studies and public databases (e.g., www.clinicaltrials.gov),
as it does not include safety/efficacy data and specifies the
conducted as opposed to planned numbers of treatments.
Patients and Methods
Definitions
For the purpose of this survey, novel cellular therapies
include the use of cells other than hematopoietic stem cells
(HSC) or of HSC for uses other than reconstitution of the
hematopoietic system. The term HSC, which is often am-
biguously used in the field of novel cellular therapies, here
indicates a mixture of stem and progenitor cells predomi-
nantly of the hematopoietic lineage. Donor lymphocyte
infusions often used in relapsing patients after HSC trans-
plantation are considered to be an integral part of the HSC
transplant procedure and are excluded.
Data collection and validation
Participating teams were requested to report their data for
2011 by indication, cell type and source, donor type, pro-
cessing method, and delivery mode. The survey followed the
traditional principles of the EBMT, concentrating on num-
bers of patients with a first cellular therapy. EBMT teams
from 49 countries (39 European and 10 affiliated countries)
were contacted for the 2011 report (EBMT survey), as were
members of the 4 participating societies, teams who had re-
ported activity to previous surveys, together with 118 addi-
tional contacts identified either through the clinicaltrials.gov
database or literature search. The non-European countries
affiliated with the EBMT were Algeria, Azerbaijan, Iran, Is-
rael, Jordan, Lebanon, Nigeria, Saudi Arabia, South Africa,
and Tunisia. Extended questionnaires, in the format dis-
played in Supplementary Table S1 (Supplementary Data are
available online at www.liebertpub.com/tea), were received
in paper form or electronically. Quality control measures, for
EBMT members only, included several established inde-
pendent systems: confirmation of validity of the entered data
by the reporting team, selective comparison of the survey
data with MED-A data sets in the EBMT ProMISE data
system, cross-checking with the National Registries, and
onsite visits of selected teams. No quality control system
could be applied to the non-EBMT reporting teams as yet.
For this survey, a number of changes in the data collection
sheet were introduced (i) to better capture and group the
disease indications and (ii) to distinguish between automated
and manual cell processing. In the accompanying guidelines,
automated cell processing was described as being appro-
priate when the cell isolation or culture was performed using
an automated device.
Transplant rates
Transplant rates, defined as the reported numbers of pa-
tients receiving cellular therapies or the number of teams
reporting treatments per 10 million inhabitants, were com-
puted for each country, without adjustments for patients
who crossed borders or received treatment in a foreign
country. Population numbers were obtained from the 2011
US census office database (www.census.gov).
Results
Participating teams
Two hundred forty-six teams in 35 countries (29 European
and 6 EBMT affiliated countries) responded to the novel
cellular therapy survey, 126 teams (24 countries) reported
performing novel cellular therapies providing detailed in-
formation on indication, cell source and type, donor type,
processing, and delivery mode, whereas 120 teams reported
no activity. In previous years, a number of teams have re-
ported using the standard EBMT transplant activity survey
sheet, allowing the inclusion of limited information. This
year, for the first time, all EBMT teams reporting information
on cellular therapies completed the extended questionnaire.
Teams that responded to the activity are listed in Appendix
in alphabetical order by country, city, EBMT CIC code (if
applicable), along with the total numbers of reported novel
cellular therapies.
Number of novel cellular therapies
and disease indications
According to the received reports, 1759 patients were
treated with novel cellular therapies, 373 (21%) with alloge-
neic, and 1386 (79%) with autologous cells (Table 1). In-
dications were musculoskeletal/rheumatological disorders
(46%; 99% autologous), cardiovascular disorders (22%; 100%
autologous), HSC graft enhancement/prevention or treat-
ment of graft-versus-host disease (GvHD), herewith grouped
using the term ‘‘hematology/oncology’’ (18%; 2% autolo-
gous), neurological disorders (2%; 83% autologous), gastro-
intestinal (1%; 68% autologous), and other indications
(12%; 77% autologous).
Among the musculoskeletal/rheumatological disorders,
the reconstructive surgery/tissue enhancement was the most
frequently reported indication, followed by cartilage and
bone repair. Among the cardiovascular disorders, myocar-
dial ischemia and peripheral artery disease were the main
reasons for a cellular therapy, followed by cardiomyopathy
and heart failure. The number of patients treated for neuro-
logical and gastrointestinal indications was rather limited
and mostly confined to multiple sclerosis (neurological) and
Crohn’s disease (gastrointestinal). Among the remaining in-
dications, most patients were treated for skin reconstruction
or for solid tumor (Table 1).
Cell type, source, and donor type
The reported cell types were mesenchymal stem/stromal
cells (MSC) (56%), HSC (23%), chondrocytes (12%), dermal
fibroblasts (3%), keratinocytes (2%), and others (4%). Of the
411 HSC treatments, 97% were autologous transplants and
74% of these were for cardiovascular diseases (Table 1). All
214 chondrocyte and 49 dermal fibroblast transplants were
autologous, whereas all 31 keratinocytes transplants were
allogeneic. From 979 MSC-based therapies, 67% were auto-
logous. The donor type was associated with the disease
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indication: autologous cells were used predominantly for
musculoskeletal/rheumatological (58%) and cardiovascular
(27%) disorders, whereas the main use of allogeneic cells was
for hematology/oncology (84%) (Fig. 1). MSC were mainly
obtained from adipose tissue (50%) or bone marrow (49%)
and mostly used for the reconstructive surgery/tissue en-
hancement within the area of musculoskeletal/rheumatolo-
gical disorders (54%) or for hematology/oncology (31%). For
the HSC treatments, cells were derived from bone marrow
(65%) or peripheral blood (35%).
The percentage of treatments using autologous versus al-
logeneic cells steadily increased from 36% in 2008 to 79% in
Table 1. Number of Reported Novel Cellular Therapy Treatments in Europe in 2011 Sorted
by Indication, Cell Source, and Donor Type
Cell type and source
Autologous Allogeneic
Indication HSC MSC Chondrocyte
Dermal
fibroblast Other HSC MSC Keratinocyte Other Autologous Allogeneic Total
Cardiovascular
Peripheral artery
disease
70 6 76 0 76
Cardiomyopathy 49 4 53 0 53
Heart failure 51 51 0 51
Myocardial
ischemia
89 1 5 95 0 95
Bypass graft 9 9 0 9
Decubitus and leg
ulcers
58 58 0 58
Other/unspecified 25 4 6 35 0 35
Musculoskeletal/rheumatological
Bone repair
(maxillofacial)
19 5 24 0 24
Bone repair
(orthopaedics)
24 36 60 0 60
Osteogenesis
imperfecta
2 2 2 2 4
Cartilage repair
(orthopaedics)
40 207 247 0 247
Muscle repair 9 9 0 9
Tendon/ligament 8 8 0 8
Reconstructive
surgery/tissue
enhancement
382 7 3 392 0 392
Scleroderma 4 3 7 0 7
Arthritis 38 38 0 38
Other/unspecified 12 1 13 0 13
Neurological
Multiple sclerosis 2 8 1 2 10 3 13
Parkinson’s 1 1 0 1
Other/unspecified 19 4 4 23 4 27
Gastrointestinal
Crohn’s disease 13 2 13 2 15
Liver insufficiency 4 0 4 4
Hematology/oncology
GvHD prevention
or treatment
13 252 0 265 265
HSC graft
enhancement
7 1 47 8 47 55
Miscellaneous
Skin reconstruction 29 36 0 31 65 31 96
Cornea repair 4 4 0 4
Diabetes 4 0 4 4
Solid tumor 10 28 38 0 38
Other 9 5 12 21 11 47 11 58
Total 397 659 214 49 67 14 320 31 8 1386 373 1759
HSC, hematopoietic stem cells; MSC, mesenchymal stromal/stem cells; GvHD, graft-versus-host disease.
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2011. This was reflected in the trends for the various therapy
areas, with the exception of hematology/oncology (Fig. 2).
Cell processing and delivery mode
Of all the grafted products, 65% required cell expansion,
3% were transduced cells, and 10% were sorted (Table 2).
Nonexpanded cells were used to treat 95% of cardiovascular,
70% of musculoskeletal/rheumatological, and 63% of neu-
rological indications, while gastrointestinal indications were
exlusively treated with expanded cells. Expanded cells were
also used for 97% of hematology/oncology treatments. Cell
sorting was applied predominantly for musculoskeletal/
rheumatological (10%) and cardiovascular (10%) disorders.
Transplanted cells were genetically transduced for 58% of
solid tumor cases, 21% of gastrointestinal (all liver insuffi-
ciency), and 6% of cardiovascular diseases. Twenty-four
percent of cells were reported to be processed using an au-
tomated device. These cells were mostly used to treat car-
diovascular (39%), musculoskeletal/rheumatological (25%),
or gastrointestinal (21%) diseases.
Just under one half (42%) of the cell grafts was delivered
intra-organ, 26% intravenously, 16% on a membrane or gel,
and 16% using a 3D scaffold (Table 3). Cells were delivered
intra-organ for 66% of cardiovascular, 58% of neurological,
and 50% of musculoskeletal/rheumatological disorders. In-
travenous delivery was reported for all hematology/oncol-
ogy treatments and about half (47%) for gastrointestinal
disorders. The use of a membrane or a gel for cell delivery
was reported almost exclusively for musculoskeletal/rheu-
matological (33%) treatments. A 3D scaffold was used for
musculoskeletal/rheumatological indications (16%), in par-
ticular for cartilage or bone repair (42%) and for cardiovas-
cular (21%) disorders—within this mainly for decubitus and
leg ulcers (74%).
Transplant rates and active teams
Reported cellular therapies were performed in a limited
number of countries and with different intensity. Figure 3
displays the reported cellular therapy transplants per 10
million inhabitants in the different European- and EBMT-
associated countries. High transplant rates (i.e., > 100 per 10
million population) were reported in Italy and Slovenia. The
number of teams reporting novel cellular therapies was also
mapped in the different European- and EBMT-associated
countries after normalization to the inhabitant numbers (Fig.
4). The number of reporting teams per 10 million inhabitants
was higher than four in Belgium, Israel, The Netherlands,
Slovenia, Spain, and Switzerland.
FIG. 1. Percentage of indications for novel cellular therapies in Europe in 2011, sorted by donor type.
FIG. 2. Comparative analysis of indications for novel cellular therapies in Europe from 2008 to 2011, sorted by donor type.
Data used for this chart were derived from the current study and the three previous reports.3–5
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Discussion
The data collected in the fourth edition of the novel cel-
lular therapy survey indicate a further increase compared to
the previous year in the number of reporting teams ( + 19%),
of total treatments reported (+ 39%), and of total treatments
reported using the dedicated form (+ 74%). These results
indicate that, thanks to the networks of the involved societies
and the introduced strategy of head-hunting for known ac-
tive teams, the program is receiving a growing recognition as
a reference platform to collect and disseminate information
that is not available in public databases or scientific publi-
cations. Moreover, the comparative analysis of data gener-
ated in the four surveys3–5 allows the identification of some
established features and developing trends.
The steady increase in the percentage of treatments using
autologous versus allogeneic cells is possibly due to a com-
bination of cultural, regulatory, and/or commercial issues.
Due to the oft claimed ‘‘minimal manipulation’’ and ‘‘homol-
ogous use’’ of the cells, the use of nonexpanded autologous
MSC for reconstructive surgery/tissue enhancement is con-
sidered by some as ‘‘tissue transplantation’’ rather than ‘‘bio-
logical drug,’’ and therefore not subject to the same rigorous
regulatory framework as are expanded MSC. This distinction
may become somewhat artificial, as shown recently in the
Celltex case.6 The number of treatments for GvHD prevention
or treatment remained relatively stable throughout the 4 years
(from 240 in 2008 to 265 in 2011), possibly due to the combi-
nation of increasing encouraging phase I/II data,7 but there is
a lack of conclusive data from adequately powered, prospec-
tive randomized controlled (PRC) trials.
The most obvious changes in the indications addressed
were in the important introduction of nonexpanded MSC
(predominantly freshly harvested from autologous adipose
Table 2. Number of Reported Novel Cellular Therapy Treatments in Europe in 2011
Sorted by Cell Processing Mode
Cell processing
Indications Nonexpanded Expanded Untransduced Transduced Unsorted Sorted Automated Manual
Cardiovascular
Peripheral artery disease 70 6 52 24 62 14 43 33
Cardiomyopathy 53 53 52 1 1 52
Heart failure 51 51 46 5 13 38
Myocardial ischemia 90 5 95 89 6 3 92
Bypass graft 9 9 9 9
Valve replacement
Decubitus + leg ulcers 58 58 58 58
Other 29 6 35 31 4 20 15
Musculoskeletal/rheumatological
Bone repair (maxillofacial) 24 24 24 5 19
Bone repair (orthopaedics) 51 9 60 51 9 31 29
Osteogenesis imperfecta 4 4 3 1 1 3
Cartilage repair (orthopaedics) 86 161 247 219 28 21 226
Muscle repair 9 9 9 9
Tendon/ligament 8 8 8 8
Reconstructive surgery/tissue
enhancement
377 15 392 387 5 126 266
Scleroderma 4 3 7 4 3 1 6
Arthritis 38 38 38 38
Other 13 13 13 13
Neurological
Multiple sclerosis 2 11 13 13 1 12
Parkinson’s 1 1 1 1
Other 23 4 27 27 27
Gastrointestinal
Crohn’s disease 15 15 15 0 15
Liver insufficiency 4 4 4 4
Hematology/oncology
GvHD prevention
or treatment
11 254 264 1 263 2 9 256
HSC graft enhancement 55 55 54 1 55
Miscellaneous
Skin reconstruction 37 59 96 70 26 8 88
Cornea repair 4 4 4 4
Diabetes 4 4 4 4
Solid tumor 32 6 16 22 14 24 2 36
Other 21 37 58 58 9 49
Total 1050 709 1708 51 1578 181 382 1377
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tissue) for plastic and reconstructive surgery, as well as
for decubitus and leg ulcers (total of 440 treatments). In
this regard, evidence of efficacy is still limited to case reports
and small series at this stage.8,9 It is thus vital that PRC
clinical trials are carried out in the next years to demonstrate
a statistical superiority of outcome for the cell-based versus
cell-free treatments. The trend in the cell delivery mode
was rather stable: the exception is of a fourfold increase in
the percentage of use of 3D scaffolds, mostly associated
with cartilage/bone repair treatments, skin reconstruction,
and ulcers.
This year, for the first time, the data collection for cell
processing included a query of whether cell graft
manufacturing included a step performed with an auto-
mated system. Although the definition of ‘‘automation’’
could be interpreted differently by the responding teams,
and respondents did not specify whether the system was
closed or streamlined with the rest of the manufacturing line,
it is nonetheless remarkable that 22% of the total treatments
were claimed to involve an automated process. A closer
analysis of the associated cell sources indicates that an au-
tomated device was introduced predominantly for the direct
implantation of freshly harvested, autologous cells. The col-
lected data are consistent with the commercial availability of
systems for the device-assisted isolation or concentration of
HSC (e.g., Sepax; Biosafe SA, www.biosafe.ch), of adipose-
derived cells (e.g., Celution; Cytori, www.cytori.com) or of
bone marrow-derived MSC (e.g., Reamer Irrigator Aspirator;
Synthes, www.synthes.com).
This year’s edition offers a perspective on cardiac cell
therapy, in an attempt to complement the collected data with
those available from other sources. Cardiovascular disease
represents a leading disease worldwide associated with a
high morbidity and mortality.10 Current therapeutic options
for patients suffering from heart failure due to myocardial
infarction or other cardiomyopathies comprise medical
treatment, ventricular assist devices, and heart transplanta-
tion. However, although heart transplantation has emerged
as the standard of care and the only curative treatment for
these patients, the key problem of organ shortage—while
Table 3. Number of Reported Novel Cellular Therapy Treatments in Europe in 2011 Sorted by Delivery Mode
Cell delivery mode
Indications Intravenous Intra-organ Membrane/gel 3D scaffold
Cardiovascular
Peripheral artery disease 7 69
Cardiomyopathy 1 52
Heart failure 20 31
Myocardial ischemia 11 84
Decubitus + leg ulcers 58
Other 10 5 20
Musculoskeletal/rheumatological
Bone repair (maxillofacial) 24
Bone repair (orthopaedics) 14 34 12
Osteogenesis imperfecta 2 2
Cartilage repair (orthopaedics) 47 120 80
Muscle repair 9
Tendon/ligament 8
Reconstructive surgery/tissue enhancement 268 118 6
Scleroderma 3 3 1
Arthritis 38
Other 13
Neurological
Multiple sclerosis 13
Parkinson’s 1
Peripheral nerve regeneration (trauma)
Other 4 23
Gastrointestinal
Crohn’s disease 7 8
Liver insufficiency 3 1
Hematology/oncology
GvHD prevention or treatment 265
HSC graft enhancement 55
Miscellaneous
Skin reconstruction 29 67
Cornea repair 4
Diabetes 4
Solid tumor 14 24
Other 25 21 12
Total 452 729 287 282
3D, three-dimensional.
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patient numbers continually rise—remains. In line with re-
generative strategies in other medical fields, the concept of
cardiac stem cell therapy has created substantial hope for the
treatment of heart failure due to myocardial infarction and
other cardiomyopathies.11 Therefore, numerous experimen-
tal and preclinical animal studies have been performed in the
past decade12 utilizing a wide range of different adult stem
cells. These include different subpopulations of bone mar-
row-derived progenitors, skeletal myoblasts, adipose-tissue
derived MSC, prenatal progenitors, blood-derived progeni-
tors as well as the recently discovered cardiac-resident stem
cells.13–19 In addition, embryonic stem cells or induced plu-
ripotent cells have been shown to be able to differentiate into
functional cardiomyocytes and are in the focus as a potential
cell source.20 Based on promising preclinical data, various
cell types have already progressed into use in clinical pilot
studies primarily aiming at demonstrating feasibility and
safety in patients suffering from acute myocardial infarction,
chronic heart disease/refractory angina, as well as ischemic
cardiomyopathy.18,21–25
Bone marrow-derived progenitors represent the most
frequently used cell source. Historically, Prof. Bodo Strauer
from the University of Du¨sseldorf was, in 2001, the first
to treat patients with acute myocardial infarction with
intracoronary-infused bone marrow mononuclear cells
(BMMC).26 Based on this study, numerous cohort studies
and randomized trials such as the BOOST study and the
REPAIR-AMI trial have been performed, testing in-
tracoronary infusion of bone marrow-derived progenitor
cells for cardiac cell therapy.21,25,27 While all study groups
reported a sufficient safety profile for these cells, the results
with regard to efficacy (i.e., improvement of ventricular
function) are still under controversial discussion. A recent
meta-analysis of 50 studies (with a total of 2625 patients)
comprising mixed results of cohort studies and PRC trials
demonstrated a significant, but still relatively limited (*4%)
FIG. 3. Number of novel cellular therapies
per 10 million inhabitants reported in Europe
in 2011.
FIG. 4. Number of teams per 10 million
inhabitants reporting novel cellular therapies
in Europe in 2011.
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improvement of left ventricular ejection fraction (LVEF) after
BMMC therapy when compared to control patients.28
In line with the collected data (Table 1), the application
of one subpopulation of BMMC, namely MSC, has been
reported to be a valid and safe option for cardiac cell
therapy. In contrast to BMMC, the use of MSC in smaller
cohort studies has demonstrated a more pronounced ef-
fect on LVEF; this, however, needs to be confirmed in
current PRC trials such as the TAC-HFT (TAC-HFT/
ClinicalTrials.gov Identifier: NCT00768066). In parallel,
the utilization of adipose tissue-derived MSC has been
investigated in several preclinical studies and has lead
to the initiation of first clinical trials such as the APOLLO
study (APOLLO/ClinicalTrials.gov Identifier: NCT0044
2806).
An interesting concept to enhance the efficacy and the
cardiogenic potential of bone marrow-derived MSC is the
concomitant application of a cardiopoietic cocktail. This has
been shown to be feasible in a preclinical study29 and has
recently led to a pilot clinical study, the C-Cure trial, where
the safety and importantly beneficial effect of cardiopoietic
MSC could be demonstrated (C-Cure/ClinicalTrials.gov
Identifier: NCT00810238) and was the basis for a randomized
multicenter trial to be initiated.
Besides the utilization of BMMC or subpopulations
thereof, the use of skeletal myoblasts has also been proposed
as a potential cell source for myocardial repair and has ad-
vanced into numerous clinical studies such as the MAGIC
trial30 and others (MYOHEART/ClinicalTrials.gov Identi-
fier: NCT00054678). However, while preclinical and initial
clinical data showed promising results, the major problem
with these cells is the lack of electrical coupling with the
hosting myocardium. Due to a lack of gap junctions and
connexins, the skeletal myoblast therapy led to severe ar-
rhythmia in some individuals and raised significant safety
concerns. However, to ensure patient safety, systematic an-
tiarrhythmic medical therapy or implantable cardioverter-
defibrillator implantation represent valid tools to treat
affected patients.31
Following the compelling evidence on the preclinical use
of cardiac resident stem cells, two pilot clinical trials em-
ploying cardiac progenitors were recently initiated22,24
(CADUCEUS/ClinicalTrials.gov Identifier: NCT00893360;
SCIPIO/ClinicalTrials.gov Identifier: NCT00474461). The
promising preliminary results will need to be confirmed, in
both the longer term and larger patient series.
Ten years after the first intracoronary clinical application
of BMMC was reported,32 the concept of cardiac cell therapy
has continuously evolved over time utilizing different
cell types and application routes (intracoronary vs. intra-
myocardial) in different clinical scenarios. While most of
these studies have focused on feasibility and safety, more
recently initiated trials are targeting assessment of the effi-
cacy of cardiac cell therapy concepts. Although the body of
clinical experience is continuously growing, several key is-
sues and questions are pending. These include not only the
definition of appropriate product release criteria and clinical
endpoints but also of a suitable cell type, route, and time of
application. In this regard, the reported data here offer the
unique opportunity to capture trends and monitor changes
in the field, in a way which reflects the conducted (as op-
posed to planned) number of treatments and which can be
communicated before a full report is published and publicly
available.
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Appendix: List of Reporting Novel Cellular Therapy Centres in Europe in 2011
Format: City, Hospital, Department, Centre Identification Code (EBMT teams), Physicians (Total treatments; allogenic/
autologous)
CIC, Centre Identification Code (as used for the standard EBMT survey)
Austria
Krems, University Krems, Regenerative Medicine and Or-
thopedics, S. Nehrer (18; 0/18)
Linz, AO Krankenhaus, 3. Medizinische Abteilung, M. A.
Fridrik (11; 0/11)
Vienna, Medical University Hospital, Traumatology, S.
Marlovits, Ch. Albrecht (7; 0/7)
Belarus
Minsk, Belorussian Center, CIC 591, O. Aleinikova (18; 18/0)
Minsk, Hospital No. 9, Belorussian Transplant Centre, N.
Milanovich (9; 6/3)
Belgium
Antwerp, University Antwerpen, Haematology, CIC 996, W.
Schroyens (50; 0/50)
Bruges, AZ Sint Jan, CIC 506, D. Selleslag, T. Lodewyck, A.v.
Hoof, J.v. Droogenbroeck, K.v. Eygen (2; 2/0)
Brussels, Clinique Universitaire St. Luc, CIC 234, X. Poire´, C.
Vermylen (1; 1/0)
Brussels, Institut Jules Bordet, Children’s Hospital, CIC 215,
D. Bron, C. Devalck, A. Ferster (1; 0/1)
Brussels, Military Hospital Queen Astrid, Burn Wound
Centre, G. Verbeken (31; 31/0)
Brussels, U.L.B. Hoˆpital Erasme, Haematology, CIC 596, B.
Bailly, A. Kentos, M. Lambermont (1; 0/1)
Brussels, University Hospital, Oncology, CIC 630, R. Schots,
F. Trullemans (1; 1/0)
Leuven, University Hospital Gasthuisberg, CIC 209, G.
Verhoef, M. Delforge, J. Maertens (1; 1/0)
Lie`ge, University Hospital Sart-Tilman, CIC 726, Y. Be´guin, B
de Prijck (8; 8/0)
Finland
Helsinki, HUCH Jorvi Hospital, Orthopaedics, Traumatol-
ogy, T. Paatela (18; 0/18)
France
Clermont Ferrand, CRCTCP, CHU Estaing, CIC 273, J.-O.
Bay, F. Deme´ocq, P. Travade (15; 1/14)
Grenoble, CHU de Grenoble, Pathologie Neurovasculaire, O.
Detante (4; 0/4)
Grenoble, Hospitalier A. Michallon, CIC 270, J.Y. Cahn, F.
Garban, P. Drillat, C. Bulabois (12; 5/7)
Lyon, Institue d’He´matologie et d’Oncologylogie Pe´diatri-
que, CIC 806, Y. Bertrand, V. Mialou (1; 1/0)
Paris, Hoˆpital Robert Debre´, Haematology-Immunology,
CIC 631, A. Baruchel, J.-H. Dalle, G. Cotten (2; 2/0)
Poitiers, CHU de Poitiers, Hoˆpital La Miletrie, Haematology,
CIC 264, M. Maillard, C. Giraud (1; 1/0)
Toulouse, University Hospital of Rangueil, Cardiology,
J. Roncalli (4; 0/4)
Germany
Dresden, Universita¨tsklinikum Carl Gustav Carus, CIC 808,
G. Ehninger, M. Bornha¨user, M. Gahr (27; 27/0)
Du¨sseldorf, Universita¨tsklinikum, Paediatrics–Haematology,
Oncology, CIC 651, A. Borkhardt, R. Meisel, F. Schuster (1;
1/0)
Frankfurt, J. W. Goethe Universita¨t, Kinderheilkunde lll, CIC
138, T. Klingebiel, P. Bader (5; 5/0)
Frankfurt, Klinikum Frankfurt Oder, Innere Medizin, CIC
190, M. Kiehl (9; 9/0)
Giessen, Universita¨tsklinikum, Paediatrics–Haematology,
Oncology, CIC 326, A. Reiter, W. Wo¨ssmann (1; 1/0)
Halle, BG-Clinic Bergmannstrost, Neurosurgery, E. Herr-
mann (16; 0/16)
Halle, Universita¨tsklinikum, KinderKlinikum, CIC 654, D.
Ko¨rholz, C. Mauz-Ko¨rholz (1; 1/0)
Hannover, Medizinische Hochschule, Haematology, Oncol-
ogy, CIC 295, A. Ganser, J. Krauter (14; 0/14)
Regensburg, Universita¨tsklinikum, Haematology, Oncology,
CIC 787, R. Andreesen, S. Corbacioglu (1; 1/0)
Tu¨bingen, Universita¨tsklinikum, Paediatrics, CIC 535, R.
Handgretinger, P. Lang (16; 13/3)
Hungary
Debrecen, University of Debrecen, Dept of Immunology, CIC
648, Z. Boda, E. Rajnavolgyi (2; 0/2)
Iran, Islamic Rep.
Shiraz, Nemazee Hospital, Haematology, Oncology, CIC
188, M. Ramzi (1; 0/1)
Teheran, Shariati Hospital, Haematology, Oncology, CIC
633, M. Jahani (3; 3/0)
Israel
Haifa, Rambam Medical Centre, Haematology, CIC 345, J.M.
Rowe (1; 1/0)
Jerusalem, Hadassah University Hospital, CIC 258, R. Or, S.
Slavin (16; 16/0)
Petach-Tikva, Beilinson Hospital, Adult Haematology, CIC
409, M. Yeshurun (1; 1/0)
Petach-Tikva, Childrens Medical Centre, Paediatrics, CIC
755, J. Stein (3; 3/0)
Italy
Bergamo, Ospedale Riuniti, CIC 658, A. Rambaldi (5; 5/0)
Bologna, 6th div, Istituto Ortopedico Rizzoli (IOR), RIT-Cell
Factory, L. Roseti (14; 0/14)
Bologna, Istituto Ortopedico Rizzoli (IOR), Orthopaedic Pa-
thology, Osteoarticular TR, D. Donati (28; 0/28)
Bolzano, Ospedale S. Maurizio, CIC 299, S. Cortelazzo, M.
Casini, I. Cavattoni (1; 1/0)
Florence, Policlinico di Careggi, CIC 304, A. Bosi, S. Guidi
(10; 4/6)
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Genoa, Istituto Giannina Gaslini, Haematology, Oncology,
CIC 274, G. Dini, E. Lanino (1; 1/0)
Genoa, Ospedale Villa Scassi, Plastic Surgery, F. Casabona
(251; 0/251)
Milan, Orthopaedic Arthroscopic Surgery International
Bioresearch Foundation, Gobbi NPO, A. Gobbi, G. Kar-
natzikos (14; 0/14)
Monza, L’Universita` di Milano-Bicocca, Ospedale San Ger-
ardo dei Tintori, CIC 544, E. Pogliani, P. Pioltelli, M. Par-
ma (1; 1/0)
Monza, Ospedale San Gerardo, CTMO–Clinica Pediatrica,
CIC 279, A. Rovelli (3; 3/0)
Padua, Centro Leucemie Infantili, CIC 285, C. Messina, M.
Pillon, E. Calore (2; 2/0)
Rome, Rome Transplant Network, CIC 756, W. Arcese, P. De
Fabritiis (3; 3/0)
Rome, Universita` ‘‘La Sapienza,’’ Plastic Surgery, A. Con-
versi, N. Scuderi (21; 0/21)
Rome, Universita` degli Studi di Roma ‘‘Tor Vergata,’’ Re-
constructive Surgery, V. Cervelli, D.J. Bottini, B. De An-
gelis (258; 0/258)
Lithuania
Kaunas, LUHS Hospital Kaunas Clinics, Sports Trauma, R.
Gudas (14; 0/14)
Netherlands
Amsterdam, Antoni Van Leeuwenhoek Cancer Institute,
Oncology, CIC 976, S. Rodenhuis, J. Baars (8; 0/8)
Amsterdam, University Medical Center VUMC, Orthopaedic
Surgery, M. Helder (5; 0/5)
Groningen, University Hospital, Haematology, CIC 546, G.
van Imhoff (1; 1/0)
Leiden, University Hospital, CIC 203, J.H. Veelken, M. Egeler
(76; 19/57)
Utrecht, UMC, Orthopaedic Surgery, D. Saris (55; 0/55)
Utrecht, UMCU/WKZ, Paediatrics, CIC 239.2, M. Bierings,
N.M. Wullffraat (5; 5/0)
Utrecht, University Hospital UMCU, CIC 239, E. Petersen (7;
7/0)
Norway
Oslo, University Hospital Rikshospitalet, Ex vivo cell lab, CIC
235, J. Brinchmann (19; 0/19)
Poland
Bydgoszcz, Nicolaus Copernicus University, Paediatrics,
Haematology, Oncology, CIC 764, M. Wysocki, J. Styc-
zynski (4; 0/4)
Cracow, University Children’s Hospital JUMC, CIC 507, J.
Gozdzik (1; 1/0)
Wroclaw, Lower Silesian Centre for Cellular Transplantation
with National Bone Marrow Donor Registry, CIC 538, A.
Lange (9; 0/9)
Wroclaw, University of Medicine, Paediatrics, CIC 817, A.
Chybicka, J. Owoc-Lempach (1; 1/0)
Russian Fed.
Moscow, Research Haematology Centre of RAS, CIC 930,
V.G. Savtchenko (7; 7/0)
Moscow, Russian Children’s Hospital, CIC 694, A. Maschan,
E. Skorobogato, E. Pachanov (33; 33/0)
Novosibirsk, Research Institute for Clinical Immunolgy, CIC
376, I. Lisukov (7; 0/7)
St. Petersburg, Pavlov Medical University, Haematology,
CIC 725, B.V. Afanasyev, L. Zubarovskaya (36; 0/36)
Serbia
Belgrade, Military Medical Academy, CIC 582, D. Stama-
tovic, S. Obradovic (5; 0/5)
Slovak Republic
Bratislava, National Cancer Institute, J. Lakota (3; 3/0)
Slovenia
Ljublijana, Educell d.o.o, N. Kregar-Velikonja (18; 0/18)
Ljublijana, UMC Ljubljana, Cardiology, B. Vrtovec (26; 0/26)
Ljublijana, University Medical Centre, Haematology, CIC
640, S. Zver, J. Pretnar (27; 0/27)
Spain
Barcelona, Hospital Clinic, CIC 214, M. Rovira (1; 1/0)
Barcelona, Institut de Tea`pia Regenerativa Tissular, F. Soler
(57; 0/57)
Barcelona, Santa Creu I Sant Pau, CIC 260, J. Sierra, S. Brunet
(2; 0/2)
Cordoba, Hospital Reina Sofia, Haematology, CIC 238, A.
Torres-Gomez (29; 0/29)
Granada, Hospital Virgen de la Nieves, Haematology, CIC
559, J.M. De Pablos Gallego, M. Jurado Chacon (3; 3/0)
Madrid, Hospital Materno-Infantil Gregorio Maran˜o´n, Pae-
diatrics, Oncology, CIC 410, C. Belendez (1; 0/1)
Madrid, Hospital de la Princesa, Haematology, CIC 236, A.
Figuera, A. Alegre (4; 2/2)
Madrid, Hospital General Universitario Gregorio Maran˜o´n,
Servicio de Haematology-UTMO, CIC 819, J.L. Diez-
Martin (4; 4/0)
Madrid, Hospital La Paz, CIC 734, R. Arrieta (3; 0/3)
Madrid, Hospital Universitario San Carlos, Haematology, J.
Diaz-Mediavilla, L. Llorente, R. Martinez (4; 0/4)
Malaga, Carlos Haya Hospital, Haematology, CIC 576, M.
Gonzalez, M. Pascual (3; 3/0)
Murcia, Hospital General Universitario Morales Meseguer,
CIC 735, V. Vicente-Garcia, I. Heras (2; 0/2)
Murcia, Hospital Virgen de la Arrixaca, CIC 323, J.M. Mor-
aleda, A. Morales Lazaro (32; 1/31)
Palma de Mallorca, Hospital Universitari Son Espases (Son
Dureta), CIC 722, J. Besalduch, M. Canaro (5; 0/5)
Pamplona, Clinica Universidad de Navarra, Cell Therapy
Area, F. Prosper Cardoso (54; 7/47)
Pamplona, Hospital de Navarra, Haematology, CIC 577, E.
Olavarria (1; 1/0)
Salamanca, Complejo Hospital, Haematology, CIC 727, D.
Caballero (14; 14/0)
Seville, Hospital Universitario Virgen del Rocio, Haematol-
ogy, CIC 769, I. Espigado, F. Marquez (2; 2/0)
Valencia, Hospital Clinico Universitario, CIC 282, C. Solano
(3; 3/0)
Sweden
Stockholm, Karolinska University Hospital, Huddinge, CIC
212, P. Ljungman (11; 11/0)
Switzerland
Basel, Bruderholzspital, Orthobiologie und Knorpelersatz,
M. Arnold (2; 0/2)
Basel, University Hospital Basel, Reconstructive Surgery, D.
Scha¨fer (3; 0/3)
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Geneva, Concept Clinic, KU. Schlaudraff (11; 0/11)
Lucerne, Kantonsspital Luzern, Herzzentrum, P. Erne (4; 0/4)
Lugano, Cardiocentro Ticino, Cardiology, D. Su¨rder (15; 0/
15)
Zu¨rich, Schulthess Klinik, Orthobiologie und Knorpelregen-
eration, M. Steinwachs (26; 0/26)
Turkey
Adana, Baskent University Adana, Haematology, CIC 589,
H. Ozdogu, C. Boga, S. Asma, S. Yuce (1; 1/0)
Ankara, Ankara Research and Education Hospital, Haema-
tology, CIC 423, F. Altuntas, M. Yu¨ksel (1; 1/0)
Ankara, Children’s Hospital, Oncology, CIC 436, B. Tunc, D.
Uckan-Cetinkaya, F. M. Azik (5; 5/0)
Ankara, Gazi University, Besevler, Haematology, CIC 169,
G. Sucak (1; 1/0)
Ankara, University of Ankara, Paediatrics, CIC 620, E. Unal,
M. Ertem (2; 2/0)
Antalya, Medical Park Hospitals, Haematology, Oncology,
CIC 919, Y. Koc (2; 2/0)
Gaziantep, Gaziantep University Medical School, Haema-
tology, CIC 402, M. Pehlivan (9; 9/0)
Istanbul, Cellest Plastic Surgery Clinic, T. Tiryaki
(31; 0/31)
Istanbul, Medical Park Bahcelievler Hospital, Paediatrics,
CIC 457, G. O¨ztu¨rk, F. Erbey (1; 1/0)
Istanbul, University of Istanbul, Haematology, CIC 760, D.
Sargin, S. Kalayoglu-Besisik (1; 1/0)
Izmir, Dokuz Eylul University, Paediatrics, Haematology, H.
O¨ren (1; 1/0)
Izmir, Dokuz Eylul University, CIC 688, H. O¨zsan (1; 1/0)
Kayseri, Erciyes University Hospital, Haematology, Oncol-
ogy, CIC 627, A. Unal, M. Cetin (1; 1/0)
Ukraine
Kiev, Kiev City BMT Centre, E. Karamanesht, V. Khomenko,
I. Korenkova (1; 1/0)
Odessa, National Medical University, I. Karpenko (5; 0/5)
United Kingdom
Bristol, Royal Hospital for Sick Children, CIC 386, J.M.
Cornish, D. Marks (9; 0/9)
Glasgow, Southern General Hospital, Institute of Neu-
rosciences, K. Muir (6; 0/6)
London, Great Ormond Street Hospital, CIC 243, P. Veys (11;
11/0)
London, Hammersmith Hospitals NHS Trust, Imperial Col-
lege, CIC 205, J. Apperley, E. Olavarria, E. Kanfer, A.
RaHaematologytulla, R. Szydlo (20; 20/0)
London, King’s College Hospital, CIC 763, A. Pagliuca (1;
1/0)
London, St. Bartholomew’s and the Royal London Hospital,
CIC 768, J. Gribben, J. Cavenagh, S. Agrawal, T. Lister (27;
0/27)
Manchester, Royal Children’s Hospital, CIC 521, R. Wynn (4;
4/0)
Manchester, School of Cancer and Enabling Sciences, CT
Unit, R. Guest (1; 0/1)
Oswestry, Oswestry Orthopaedic Hospital, P. Harrison (28;
0/28)
Sheffield, Teaching Hospitals NHS Trust, Children’s Hospi-
tal, CIC 778, J. Snowden, A. Vora (2; 1/1)
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